Scleroderma Queensland
  • Home
  • About Us
    • Members' Stories
  • Become a Member
  • Donations
  • FUNDRAISING
  • News
  • EVENTS
  • Group Meetings
  • Contact Us

CCP Antibodies Linked to ILD, Worse Lung Function in SSc Patients

9/12/2022

 
An anti-CCP antibody test may help with early detection of ILD by Margarida Maia, PhD
Picture
People with systemic scleroderma (SSc) who test positive for cyclic citrullinated peptide (CCP) antibodies are more likely than those who test negative to develop interstitial lung disease (ILD) — when the lungs become scarred — and have worse lung function.

​That’s according to data from a South Korean study that included people with systemic lupus erythematosus (SLE) or myositis, disorders with symptoms that sometimes overlap with scleroderma.
The study, “A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and interstitial lung disease in systemic sclerosis,” was published in Scientific Reports.

A CCP antibody test looks for anti-CCP antibodies in the blood. They are a type of autoantibody that wrongfully turns against healthy tissues in the joints.
A positive test for anti-CCP antibodies in the blood can indicate rheumatoid arthritis, an autoimmune disease that causes pain, swelling, and stiffness in the joints. It can also indicate the likelihood of developing symptoms outside the joints, such as ILD.

Scleroderma occurs when autoantibodies attack the skin’s connective tissue, the body’s framework. In scleroderma, producing a protein called collagen in excessive amounts makes the skin harden and scar. In SSc, a type of scleroderma, the attack includes other organs. If the joints are affected, patients may have arthritis-like symptoms.

It’s not known if anti-CCP antibodies play a role in developing SSc. What the researchers knew is that anti-CCP antibodies in the blood are linked to lung fibrosis (scarring) with SSc. They report now that “an anti-CCP antibody test may be helpful for early detection of ILD in SSc patients.”

​The study included 260 people with a diagnosis of SSc, 936 people with SLE, and 156 with polymyositis/dermatomyositis (PM/DM), two types of myositis, who received care at a Seoul hospital between January 2005 and May 2021.

Continue reading...


Comments are closed.

    Author

    Scleroderma Queensland Support Group

    Archives

    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    February 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    March 2020

    Categories

    All
    Announcements
    Community
    Members Stories
    Research
    Resources
    Scleroderma
    Support
    Support Group Meetings
    Useful Links

Scleroderma ​Association of Queensland

​About Us | Members' Stories | Group Meetings | Become a Member
Donate now
Phone 0468 801 021  Email info@scleroderma.org.au
Postal Address PO Box 316, Salisbury Qld 4107
©Scleroderma Association of Queensland. ​All rights reserved. Website by Grey and Grey. 
  • Home
  • About Us
    • Members' Stories
  • Become a Member
  • Donations
  • FUNDRAISING
  • News
  • EVENTS
  • Group Meetings
  • Contact Us